Trial NCT04746183; ISRCTN27106947; EudraCT 2020-001860-2
Publication AGILE CST-2 - Khoo SH, Lancet Infect Dis (2022) (published paper)
Dates: 2020-10-18 to 2022-03-16
Funding: Mixed (Ridgeback Biotherapeutics; Medical Research Council; the Wellcome Trust; UK National Institute of Healthcare Research; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections; UK Medical Research Council. Molnupiravir was provided by Ridgeback Biotherapeutics as 200mg capsules (with matching placebo).)
Conflict of interest: Yes